Oropharyngeal tularemia is a clinical form of infection caused by Francisella tularensis, acquired through ingestion of contaminated water, food, or undercooked meat, presenting with severe pharyngitis/tonsillitis and prominent cervical lymphadenopathy. [1-3] It is the predominant form in waterborne outbreaks and is a re-emerging zoonosis in the Northern Hemisphere. [2][4]
The following figure illustrates the modes of acquisition and clinical manifestations of tularemia, including the oropharyngeal form:
1. History
- Key HPI questions: Ask about ingestion of untreated/unchlorinated water (wells, springs, streams), undercooked wild game (especially rabbit/hare), or raw food potentially contaminated by rodent excrement [2-3]
- Symptom characterization: Severe sore throat, odynophagia, neck swelling/pain, fever with abrupt onset (38–41.5°C), chills, rigors [1][3][6]
- Timing: Incubation period 3–5 days (range 1–14 days); patients typically seek care after a median of 3 days of illness [7-8]
- Associated symptoms: Headache, malaise, fatigue, anorexia, myalgia, arthralgia, nausea/vomiting, diarrhea, abdominal pain [1-3]
- Important negatives: Absence of skin ulcer (distinguishes from ulceroglandular form), absence of conjunctivitis, absence of cough/dyspnea (though secondary pneumonia can develop) [2-3]
2. Alarm Features
- Airway compromise from pronounced cervical or retropharyngeal lymphadenopathy — can cause stridor, drooling, or inability to swallow [3]
- Progression to typhoidal form: high fever, confusion, stupor, behavioral changes, sepsis without localizing signs [2-3]
- Secondary pneumonia: cough, dyspnea, pleuritic chest pain — can rapidly progress to respiratory failure [3][9]
- Suppurative lymphadenopathy (occurs in ~30% of patients with lymphadenopathy), which may fistulize [2][10]
- Signs of meningitis (rare): headache, neck stiffness, altered mental status [2]
- Pulse-temperature dissociation noted in up to 42% of patients [3]
- Immunocompromised patients (especially those on anti-TNF-α agents) are at particular risk for severe/disseminated disease [11]
3. Medications
- First-line (mild-moderate oropharyngeal disease):
- Ciprofloxacin 500 mg PO BID × 10–14 days, or levofloxacin 500 mg PO daily [2][7][12]
- Doxycycline 100 mg PO BID × 14–21 days [2][7]
- First-line (severe disease):
- Gentamicin 5 mg/kg IV/IM daily × minimum 10 days [7][13]
- Streptomycin 1 g IM BID × minimum 10 days [7]
- 2025 CDC update designates fluoroquinolones and doxycycline as first-line for outbreaks of any size [12]
- Ineffective/contraindicated: Beta-lactams (intrinsic resistance due to beta-lactamase production), most macrolides, anti-tuberculosis agents [2][10]
- Cautions: Fluoroquinolones — tendon rupture risk, QT prolongation; doxycycline — photosensitivity, avoid in pregnancy (gentamicin preferred for severe disease in pregnancy); aminoglycosides — nephrotoxicity, ototoxicity requiring renal dose adjustment [2][7]
- Pediatric dosing: Gentamicin 2.5 mg/kg IV/IM TID; ciprofloxacin 15 mg/kg IV/PO BID; streptomycin 15 mg/kg IM BID [13]
4. Diet
- Acute phase: Soft diet or liquids as tolerated given severe odynophagia; maintain adequate hydration
- Prevention-focused dietary counseling:
- Avoid drinking untreated water from wells, springs, or streams in endemic areas [2][14]
- Thoroughly cook wild game meat, especially rabbit and hare [2]
- Avoid handling or consuming food potentially contaminated by rodent excrement [2]
5. Review of Systems
- HEENT: Sore throat severity, dysphagia, odynophagia, trismus, voice changes (muffled/"hot potato" voice), oral ulcers, ear pain (otitis media is a known complication) [2]
- Constitutional: Fever pattern, chills, rigors, night sweats, weight loss, fatigue [3]
- Respiratory: Cough (dry or productive), dyspnea, pleuritic chest pain, hemoptysis — screen for secondary pneumonia [3]
- GI: Nausea, vomiting, diarrhea, abdominal pain [1][3]
- Neurologic: Headache, confusion, behavioral changes — screen for meningitis/typhoidal progression [2]
- Musculoskeletal: Myalgia, arthralgia [2]
- Skin: Rash (erythema nodosum is a known complication) [2]
6. Collateral History and Family History
- Critical exposure history:
- Contact with wild animals (rabbits, hares, rodents) — hunting, trapping, butchering, farming [3][9]
- Tick or deerfly bites [1]
- Drinking from untreated water sources (wells, springs, streams) [2][14]
- Landscaping, mowing (aerosolization of contaminated material) [1]
- Geographic location — endemic areas (south-central US states: Missouri, Arkansas, Oklahoma; Scandinavia; Turkey; Kosovo) [2][15]
- Occupational exposure: hunters, farmers, veterinarians, laboratory workers [3][9]
- Household contacts: Ask about similar symptoms in family members — cluster cases suggest a common waterborne or foodborne source [14]
- Family history is generally not contributory, though immunocompromising conditions in the patient increase risk of severe disease [2]
7. Risk Factors
- Ingestion of contaminated water (wells, springs contaminated by rodent carcasses) — the primary risk factor for oropharyngeal form [2][14]
- Consumption of undercooked wild game (rabbit, hare) [2][9]
- Rural residence in endemic areas [3]
- Occupational exposure: Hunters, trappers, butchers, farmers, landscapers, laboratory workers [3][9]
- Immunocompromised status (HIV, anti-TNF-α therapy, organ transplant) — associated with more severe and atypical presentations [2][11]
- Seasonal variation: Late summer to autumn peaks in many regions [16]
- Precarious living conditions (war zones, areas with poor water sanitation) — historically associated with oropharyngeal outbreaks [2]
8. Differential Diagnosis
- Streptococcal pharyngitis/peritonsillar abscess: Exudative pharyngitis with cervical lymphadenopathy; rapid strep test/culture distinguishes; tularemia typically has more prominent systemic toxicity and fails beta-lactam therapy [17]
- Infectious mononucleosis (EBV): Exudative pharyngitis, cervical lymphadenopathy, fatigue; heterophile antibody/monospot and atypical lymphocytes help differentiate
- Cervical tuberculosis/scrofula: Chronic cervical lymphadenopathy with caseating granulomas on biopsy — tularemia can produce identical histopathology and is a key mimic [18]
- Lymphoma: Persistent cervical lymphadenopathy; tularemia lymph nodes on PET-CT can appear intensely hypermetabolic, mimicking malignancy [19]
- Cat scratch disease (Bartonella henselae): Lymphadenopathy with animal exposure; serology and PCR distinguish [20]
- Diphtheria: Exudative pharyngitis with pseudomembrane; rare in vaccinated populations
- Deep space neck infection/retropharyngeal abscess: Fever, neck swelling, dysphagia; CT neck with contrast differentiates
- Plague (Yersinia pestis): Cervical buboes with systemic toxicity; consider in bioterrorism context
9. Past Medical History
- Immunocompromising conditions: HIV/AIDS, organ transplant, immunosuppressive medications (especially anti-TNF-α agents) — increased risk of severe/disseminated disease [2][11]
- Prior tularemia episodes: Reinfection is possible though some immunity develops
- Chronic illness: Diabetes, renal disease (affects aminoglycoside dosing) [7]
- Surgical history: Prior head/neck surgery or radiation may alter lymphatic drainage patterns
- Beta-lactam treatment failure: A history of pharyngitis unresponsive to amoxicillin/penicillin should raise suspicion for tularemia [17]
10. Physical Exam
- Vital signs: High fever (38–41.5°C), tachycardia (note pulse-temperature dissociation in ~42%), assess for hemodynamic instability [3]
- Oropharynx: Exudative pharyngitis or tonsillitis, sometimes with mucosal ulceration; stomatitis may be present [1-3]
- Neck: Tender, prominent cervical lymphadenopathy (anterior cervical, submandibular, preparotid); assess for fluctuance suggesting suppuration; retropharyngeal fullness on exam [1][3][6]
- Airway assessment: Stridor, drooling, trismus, muffled voice — signs of impending airway compromise from retropharyngeal lymphadenopathy
- Skin: Examine for erythema nodosum, rash; absence of skin ulcer expected in oropharyngeal form [2]
- Lungs: Auscultate for crackles, decreased breath sounds (secondary pneumonia) [3]
- Abdomen: Hepatosplenomegaly may be present in disseminated disease [9]
- Neurologic: Mental status assessment for typhoidal progression [2]
11. Lab Studies
- Serology (gold standard for diagnosis): Microagglutination test — seroconversion or ≥4-fold rise in titer between acute and convalescent sera is diagnostic; single titer ≥1:160 is highly suggestive; antibodies typically detectable by day 10–14 of illness [2][21]
- PCR: Highly sensitive and specific from oropharyngeal swabs, lymph node aspirates; enables rapid diagnosis [2][11]
- Culture: Requires cysteine-enriched media (chocolate agar, cysteine heart agar); must notify laboratory of suspicion due to extreme biosafety risk to lab personnel [2][7][20]
- Expected lab abnormalities:
- Leukocytosis (or normal WBC), elevated ESR [13]
- Thrombocytopenia [13]
- Hyponatremia [13]
- Elevated hepatic transaminases [13][21]
- Elevated CPK, myoglobinuria (less common) [13]
- Sterile pyuria [13]
- Rule-out labs: Rapid strep test, monospot, HIV, blood cultures (standard), CBC with differential, CMP, CRP/ESR
12. Imaging
- CT neck with contrast: First-line imaging for oropharyngeal tularemia — evaluates for suppurative lymphadenopathy, retropharyngeal abscess, conglomerate lymphadenopathy, and airway compromise [6]
- Ultrasound of neck: Can assess lymph node characteristics (suppurative vs. reactive); useful for serial monitoring and guiding aspiration [6]
- Chest X-ray: Obtain if respiratory symptoms present — may show peribronchial infiltrates, hilar lymphadenopathy, pleural effusion [3][21]
- CT chest: If CXR abnormal or concern for pneumonic tularemia — mediastinal lymphadenopathy, pulmonary nodules, pleural effusion [19]
- PET-CT: Not routinely indicated; intensely hypermetabolic lymph nodes can mimic lymphoma and lead to unnecessary biopsies [19]
- Imaging unnecessary in mild, uncomplicated oropharyngeal disease with small, non-suppurative lymph nodes
13. Special Tests
- Tularemia serology (microagglutination or ELISA): Primary diagnostic modality; paired sera 2–4 weeks apart [2][21]
- PCR for F. tularensis DNA: From pharyngeal swabs, lymph node aspirates, or blood — rapid confirmation [2][11]
- Direct fluorescent antibody (DFA): Can be performed on clinical specimens [13]
- Fine needle aspiration (FNA) of lymph nodes: For culture, PCR, and cytology — helps distinguish from TB and lymphoma; send for AFB stain, flow cytometry if malignancy suspected [18]
- Centor/McIsaac score: Useful to risk-stratify pharyngitis initially, but tularemia pharyngitis will not respond to standard strep treatment
- Radiological evaluation of lymph nodes at admission may help predict which patients will require surgical drainage [6]
14. ECG
- Routine ECG is not standard for uncomplicated oropharyngeal tularemia
- Indications for ECG: Chest pain, dyspnea, palpitations, or hemodynamic instability
- Myocarditis is a very rare but reported complication of tularemia; pericarditis and endocarditis are anecdotal [22-23]
- If myocarditis suspected: look for sinus tachycardia, ST-T wave changes, conduction delays, low voltage [22-23]
- Pulse-temperature dissociation (relative bradycardia) is a classic finding in tularemia and should not be confused with cardiac pathology [3]
15. Assessment
- Oropharyngeal tularemia is a localized form with generally favorable prognosis when treated early with appropriate antibiotics [2][4]
- Severity stratification:
- Mild: Pharyngitis with small reactive cervical lymph nodes, stable vitals
- Moderate: Exudative tonsillitis with prominent lymphadenopathy, high fever, systemic symptoms
- Severe: Suppurative/conglomerate lymphadenopathy, retropharyngeal extension, airway compromise, signs of dissemination (pneumonia, sepsis, meningitis)
- Typical presentation: Severe sore throat + exudative pharyngitis + tender cervical lymphadenopathy + high fever + exposure history (contaminated water/food) [1][3][6]
- Atypical presentations: Isolated cervical lymphadenopathy without pharyngitis (mimicking TB or lymphoma); GI-predominant symptoms [18-19]
- Complications: Lymph node suppuration (~30%), chronic lymphadenopathy (months), secondary pneumonia, sepsis, meningitis (rare), erythema nodosum, otitis media [2][9]
- Treatment failure rate ~15% even with appropriate antibiotics; higher with delayed treatment (>2–3 weeks after onset) [6][10]
16. Treatment Plan
Initial stabilization:
- Assess and secure airway if retropharyngeal lymphadenopathy causes compromise
- IV fluids for dehydration from poor oral intake
- Antipyretics (acetaminophen/ibuprofen) for fever and pain
Antibiotic therapy (per 2025 CDC recommendations): [12]
- Step-down from IV aminoglycoside to oral fluoroquinolone or doxycycline once clinically improved is a rational approach [7]
- Fluoroquinolones are associated with lower relapse rates (~5–10%) compared to tetracyclines (~10–15%) [2]
Surgical intervention:
- Lymph node drainage or excision required in ~23% of patients with suppurative lymphadenitis, abscess, necrosis, or conglomerate lymphadenopathy [6]
- Incision and drainage of retropharyngeal abscess if present
Notify public health authorities — tularemia is a nationally notifiable disease and a CDC Tier 1 select agent [3][15]
17. Disposition
- Admission criteria:
- Inability to tolerate oral intake/medications
- Airway compromise or concern for retropharyngeal abscess
- Severe systemic toxicity, hemodynamic instability, sepsis
- Immunocompromised host
- Need for IV aminoglycoside therapy (severe disease)
- Suspected secondary pneumonia or disseminated disease
- Discharge criteria:
- Tolerating oral antibiotics and fluids
- Stable vitals, defervescing
- No airway concerns
- Reliable follow-up arranged
- Observation indications: Moderate disease with borderline oral tolerance; awaiting imaging results for lymph node assessment
- Specialist consultation triggers:
- Infectious disease: All confirmed/suspected cases for antibiotic guidance and public health coordination
- ENT/surgery: Suppurative lymphadenopathy requiring drainage, retropharyngeal abscess, airway concerns
- Pulmonology/critical care: Secondary pneumonia, respiratory failure
18. Follow Up / Return Precautions
- Follow-up timing: Recheck in 5–7 days after initiating antibiotics to assess clinical response; repeat at 2–4 weeks for convalescent serology [2][21]
- Symptoms requiring immediate reassessment:
- Worsening neck swelling, difficulty breathing or swallowing, stridor
- Persistent or recurrent high fever despite ≥72 hours of appropriate antibiotics
- New cough, chest pain, or dyspnea (concern for secondary pneumonia)
- Confusion, altered mental status
- Inability to tolerate oral medications or fluids
- Patient counseling:
- Convalescence can be prolonged (weeks to months) with persistent fatigue and lymphadenopathy even after successful treatment [2][9]
- Lymph node suppuration may develop weeks after treatment initiation — report new or worsening neck swelling [2][10]
- No person-to-person transmission — standard precautions are adequate [3]
- Avoid untreated water sources and undercooked wild game in the future [2]
- Expected recovery: Clinical improvement typically within 48–72 hours of appropriate antibiotics; lymphadenopathy may take weeks to months to fully resolve; relapse rate is 5–15% depending on antibiotic class used [2][10]
References
1. Tickborne Diseases of the United States: A Reference Manual for Healthcare Providers Sixth Edition. — Nancy Shadick MD MPH, Nancy Maher MPH, Dennis Hoak MD United States Centers for Disease Control and Prevention (2022). 2022.
2. Tickborne Diseases of the United States: A Reference Manual for Healthcare Providers Sixth Edition. — Nancy Shadick MD MPH, Nancy Maher MPH, Dennis Hoak MD United States Centers for Disease Control and Prevention (2022). 2022.
3. Tickborne Diseases of the United States: A Reference Manual for Healthcare Providers Sixth Edition. — Nancy Shadick MD MPH, Nancy Maher MPH, Dennis Hoak MD United States Centers for Disease Control and Prevention (2022). 2022.
4. Tularaemia: Clinical Aspects in Europe. — Maurin M, Gyuranecz M. The Lancet. Infectious Diseases. 2016.
5. Tularaemia: Clinical Aspects in Europe. — Maurin M, Gyuranecz M. The Lancet. Infectious Diseases. 2016.
6. Tularemia as a Biological Weapon: Medical and Public Health Management. — Dennis DT, Inglesby TV, Henderson DA, et al. The Journal of the American Medical Association. 2001.
7. Tularemia as a Biological Weapon: Medical and Public Health Management. — Dennis DT, Inglesby TV, Henderson DA, et al. The Journal of the American Medical Association. 2001.
8. Tularemia for Clinicians: An Up-to-Date Review on Epidemiology, Diagnosis, Prevention and Treatment. — Antonello RM, Giacomelli A, Riccardi N. European Journal of Internal Medicine. 2025.
9. Tularemia for Clinicians: An Up-to-Date Review on Epidemiology, Diagnosis, Prevention and Treatment. — Antonello RM, Giacomelli A, Riccardi N. European Journal of Internal Medicine. 2025.
10. Going Down the Rabbit Hole. — Burdick KJ, Ealick W, Vargas Acevedo H, Sectish TC, Sandora TJ. The New England Journal of Medicine. 2024.
11. Going Down the Rabbit Hole. — Burdick KJ, Ealick W, Vargas Acevedo H, Sectish TC, Sandora TJ. The New England Journal of Medicine. 2024.
12. Evaluation of the Clinical Characteristics, Laboratory Parameters, and Antibiotic Treatment in Patients Diagnosed With Tularemia. — Çakır Kıymaz Y, Bolat S, Katırcı B, et al. Journal of Infection and Chemotherapy : Official Journal of the Japan Society of Chemotherapy. 2025.
13. Evaluation of the Clinical Characteristics, Laboratory Parameters, and Antibiotic Treatment in Patients Diagnosed With Tularemia. — Çakır Kıymaz Y, Bolat S, Katırcı B, et al. Journal of Infection and Chemotherapy : Official Journal of the Japan Society of Chemotherapy. 2025.
14. Practice Guidelines for the Diagnosis and Management of Skin and Soft Tissue Infections: 2014 Update by the Infectious Diseases Society of America. — Stevens DL, Bisno AL, Chambers HF, et al. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 2014.
15. Practice Guidelines for the Diagnosis and Management of Skin and Soft Tissue Infections: 2014 Update by the Infectious Diseases Society of America. — Stevens DL, Bisno AL, Chambers HF, et al. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 2014.
16. Clinical Recognition and Management of Tularemia in Missouri: A Retrospective Records Review of 121 Cases. — Weber IB, Turabelidze G, Patrick S, et al. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 2012.
17. Clinical Recognition and Management of Tularemia in Missouri: A Retrospective Records Review of 121 Cases. — Weber IB, Turabelidze G, Patrick S, et al. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 2012.
18. Multifaceted effects of F rancisella tularensis on human neutrophil function and lifespan. — Kinkead LC, Allen LA. Immunological Reviews. 2016.
19. Multifaceted effects of F rancisella tularensis on human neutrophil function and lifespan. — Kinkead LC, Allen LA. Immunological Reviews. 2016.
20. Tularemia Treatment: Experimental and Clinical Data. — Maurin M, Pondérand L, Hennebique A, et al. Frontiers in Microbiology. 2023.
21. Tularemia Treatment: Experimental and Clinical Data. — Maurin M, Pondérand L, Hennebique A, et al. Frontiers in Microbiology. 2023.
22. Pulmonary tularaemia in a female adolescent with inflammatory bowel disease receiving infliximab: Do not miss the diagnosis. — Schwarzová V, Schwarz J, Mitrová K, et al. Pediatric Pulmonology. 2023.
23. Pulmonary tularaemia in a female adolescent with inflammatory bowel disease receiving infliximab: Do not miss the diagnosis. — Schwarzová V, Schwarz J, Mitrová K, et al. Pediatric Pulmonology. 2023.
24. Tularemia Antimicrobial Treatment and Prophylaxis: CDC Recommendations for Naturally Acquired Infections and Bioterrorism Response - United States, 2025. — Nelson CA, Meaney-Delman D, Fleck-Derderian S, Winberg J, Mead PS. MMWR. Recommendations and Reports : Morbidity and Mortality Weekly Report. Recommendations and Reports. 2025.
25. Tularemia Antimicrobial Treatment and Prophylaxis: CDC Recommendations for Naturally Acquired Infections and Bioterrorism Response - United States, 2025. — Nelson CA, Meaney-Delman D, Fleck-Derderian S, Winberg J, Mead PS. MMWR. Recommendations and Reports : Morbidity and Mortality Weekly Report. Recommendations and Reports. 2025.
26. Wilderness Medical Society Clinical Practice Guidelines for the Prevention and Management of Tick-Borne Illness in the United States. — Ho BM, Davis HE, Forrester JD, et al. Wilderness & Environmental Medicine. 2021.
27. Wilderness Medical Society Clinical Practice Guidelines for the Prevention and Management of Tick-Borne Illness in the United States. — Ho BM, Davis HE, Forrester JD, et al. Wilderness & Environmental Medicine. 2021.
28. Oropharyngeal Tularemia Outbreak Linked to Drinking Contaminated Tap Water in North-Western Iran. — Esmaeili P, Khayatzadeh S, Maurin M, et al. Diagnostic Microbiology and Infectious Disease. 2024.
29. Oropharyngeal Tularemia Outbreak Linked to Drinking Contaminated Tap Water in North-Western Iran. — Esmaeili P, Khayatzadeh S, Maurin M, et al. Diagnostic Microbiology and Infectious Disease. 2024.
30. Tularemia - United States, 2001-2010. — MMWR. Morbidity and Mortality Weekly Report. 2013.
31. Tularemia - United States, 2001-2010. — MMWR. Morbidity and Mortality Weekly Report. 2013.
32. Long-Term Survival of Virulent Tularemia Pathogens Outside a Host in Conditions That Mimic Natural Aquatic Environments. — Golovliov I, Bäckman S, Granberg M, et al. Applied and Environmental Microbiology. 2021.
33. Long-Term Survival of Virulent Tularemia Pathogens Outside a Host in Conditions That Mimic Natural Aquatic Environments. — Golovliov I, Bäckman S, Granberg M, et al. Applied and Environmental Microbiology. 2021.
34. Tularemia in Pediatric Patients: A Case Series and Review of the Literature. — Kossadoum RF, Baron A, Parizot M, et al. The Pediatric Infectious Disease Journal. 2025.
35. Tularemia in Pediatric Patients: A Case Series and Review of the Literature. — Kossadoum RF, Baron A, Parizot M, et al. The Pediatric Infectious Disease Journal. 2025.
36. A Clinical Pitfall in Caseating Necrotizing Granulomatous Lymphadenitis: Tularemia. — Özan Köse S, Erdem H, Köse ÖC, Yılmaz Ertürk F. Diagnostic Microbiology and Infectious Disease. 2025.
37. A Clinical Pitfall in Caseating Necrotizing Granulomatous Lymphadenitis: Tularemia. — Özan Köse S, Erdem H, Köse ÖC, Yılmaz Ertürk F. Diagnostic Microbiology and Infectious Disease. 2025.
38. Pulmonary Tularemia: A Diagnosis Not to Overlook. — Zaghdoudi A, Robin F, Moulinie J, et al. International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases. 2026.
39. Pulmonary Tularemia: A Diagnosis Not to Overlook. — Zaghdoudi A, Robin F, Moulinie J, et al. International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases. 2026.
40. Guide to Utilization of the Microbiology Laboratory for Diagnosis of Infectious Diseases: 2024 Update by the Infectious Diseases Society of America (IDSA) and the American Society for Microbiology (ASM). — Miller JM, Binnicker MJ, Campbell S, et al. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 2024.
41. Guide to Utilization of the Microbiology Laboratory for Diagnosis of Infectious Diseases: 2024 Update by the Infectious Diseases Society of America (IDSA) and the American Society for Microbiology (ASM). — Miller JM, Binnicker MJ, Campbell S, et al. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 2024.
42. Tick-Borne Diseases in the United States. — Spach DH, Liles WC, Campbell GL, et al. The New England Journal of Medicine. 1993.
43. Tick-Borne Diseases in the United States. — Spach DH, Liles WC, Campbell GL, et al. The New England Journal of Medicine. 1993.
44. Tularemia: An Experience of 13 Cases Including a Rare Myocarditis in a Referral Center in Eastern Switzerland (Central Europe) and a Review of the Literature. — Frischknecht M, Meier A, Mani B, et al. Infection. 2019.
45. Tularemia: An Experience of 13 Cases Including a Rare Myocarditis in a Referral Center in Eastern Switzerland (Central Europe) and a Review of the Literature. — Frischknecht M, Meier A, Mani B, et al. Infection. 2019.
46. ACCF/AHA/CDC Conference Report on Emerging Infectious Diseases and Biological Terrorism Threats. Task Force III: Prevention and Control of Cardiovascular Complications of Emerging Infectious Diseases and Potential Biological Terrorism Agents and Diseases. — Cooper LT, Mensah GA, Baddour LM, et al. Journal of the American College of Cardiology. 2007.
47. ACCF/AHA/CDC Conference Report on Emerging Infectious Diseases and Biological Terrorism Threats. Task Force III: Prevention and Control of Cardiovascular Complications of Emerging Infectious Diseases and Potential Biological Terrorism Agents and Diseases. — Cooper LT, Mensah GA, Baddour LM, et al. Journal of the American College of Cardiology. 2007.